DGIdb 3.0: a Redesign and Expansion of the Drug-gene Interaction Database

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2017 Nov 21

PMID 29156001

Citations 452

Authors

Kelsy C Cotto

Alex H Wagner

Yang-Yang Feng

Susanna Kiwala

Adam C Coffman

Gregory Spies

Alex Wollam

Nicholas C Spies

Obi L Griffith

Malachi Griffith

Affiliations

Soon will be listed here.

Abstract

The drug-gene interaction database (DGIdb, www.dgidb.org) consolidates, organizes and presents drug-gene interactions and gene druggability information from papers, databases and web resources. DGIdb normalizes content from 30 disparate sources and allows for user-friendly advanced browsing, searching and filtering for ease of access through an intuitive web user interface, application programming interface (API) and public cloud-based server image. DGIdb v3.0 represents a major update of the database. Nine of the previously included 24 sources were updated. Six new resources were added, bringing the total number of sources to 30. These updates and additions of sources have cumulatively resulted in 56 309 interaction claims. This has also substantially expanded the comprehensive catalogue of druggable genes and anti-neoplastic drug-gene interactions included in the DGIdb. Along with these content updates, v3.0 has received a major overhaul of its codebase, including an updated user interface, preset interaction search filters, consolidation of interaction information into interaction groups, greatly improved search response times and upgrading the underlying web application framework. In addition, the expanded API features new endpoints which allow users to extract more detailed information about queried drugs, genes and drug-gene interactions, including listings of PubMed IDs, interaction type and other interaction metadata.

Citing Articles

Genetically supported targets and drug repurposing for brain aging: A systematic study in the UK Biobank.

Yi F, Yuan J, Somekh J, Peleg M, Zhu Y, Jia Z Sci Adv. 2025; 11(11):eadr3757.

PMID: 40073132 PMC: 11900869. DOI: 10.1126/sciadv.adr3757.

Harnessing the power of genomics in hypertension: tip of the iceberg?.

Naderi H, Warren H, Munroe P Camb Prism Precis Med. 2025; 3:e2.

PMID: 40071139 PMC: 11894416. DOI: 10.1017/pcm.2025.1.

Integrating transcriptomic data with a novel drug efficacy prediction model for TCM active compound discovery.

Li Y, Shen Y, Cai Y, Zhang Y, Gao J, Huang L Sci Rep. 2025; 15(1):7688.

PMID: 40044718 PMC: 11882833. DOI: 10.1038/s41598-024-82498-1.

Mendelian randomization reveals plasminogen as a common therapeutic target for myocardial infarction and atrial fibrillation.

Charati H, Hamta A J Cardiovasc Thorac Res. 2025; 16(4):249-257.

PMID: 40027362 PMC: 11866770. DOI: 10.34172/jcvtr.33269.

Integrative systems biology framework discovers common gene regulatory signatures in mechanistically distinct inflammatory skin diseases.

Mishra B, Gou Y, Tan Z, Wang Y, Hu G, Athar M NPJ Syst Biol Appl. 2025; 11(1):21.

PMID: 40016271 PMC: 11868562. DOI: 10.1038/s41540-025-00498-x.

References

Kim S, Thiessen P, Bolton E, Chen J, Fu G, Gindulyte A . PubChem Substance and Compound databases. Nucleic Acids Res. 2015; 44(D1):D1202-13. PMC: 4702940. DOI: 10.1093/nar/gkv951. View

Fisch K, Meissner T, Gioia L, Ducom J, Carland T, Loguercio S . Omics Pipe: a community-based framework for reproducible multi-omics data analysis. Bioinformatics. 2015; 31(11):1724-8. PMC: 4443682. DOI: 10.1093/bioinformatics/btv061. View

Mock A, Murphy S, Morris J, Marass F, Rosenfeld N, Massie C . CVE: an R package for interactive variant prioritisation in precision oncology. BMC Med Genomics. 2017; 10(1):37. PMC: 5445311. DOI: 10.1186/s12920-017-0261-6. View

Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

Law V, Knox C, Djoumbou Y, Jewison T, Guo A, Liu Y . DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2013; 42(Database issue):D1091-7. PMC: 3965102. DOI: 10.1093/nar/gkt1068. View

Bento A, Gaulton A, Hersey A, Bellis L, Chambers J, Davies M . The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2013; 42(Database issue):D1083-90. PMC: 3965067. DOI: 10.1093/nar/gkt1031. View

Brown G, Hem V, Katz K, Ovetsky M, Wallin C, Ermolaeva O . Gene: a gene-centered information resource at NCBI. Nucleic Acids Res. 2014; 43(Database issue):D36-42. PMC: 4383897. DOI: 10.1093/nar/gku1055. View

. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2014; 43(Database issue):D1049-56. PMC: 4383973. DOI: 10.1093/nar/gku1179. View

Griffith M, Griffith O, Coffman A, Weible J, McMichael J, Spies N . DGIdb: mining the druggable genome. Nat Methods. 2013; 10(12):1209-10. PMC: 3851581. DOI: 10.1038/nmeth.2689. View

10.

Griffith M, Spies N, Krysiak K, McMichael J, Coffman A, Danos A . CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017; 49(2):170-174. PMC: 5367263. DOI: 10.1038/ng.3774. View

11.

Simon G, Somaiah N . A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer. 2014; 15(1):21-51. DOI: 10.1016/j.cllc.2013.11.009. View

12.

Hopkins A, Groom C . The druggable genome. Nat Rev Drug Discov. 2002; 1(9):727-30. DOI: 10.1038/nrd892. View

13.

Patterson S, Liu R, Statz C, Durkin D, Lakshminarayana A, Mockus S . The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genomics. 2016; 10:4. PMC: 4715272. DOI: 10.1186/s40246-016-0061-7. View

14.

Cheng D, Mitchell T, Zehir A, Shah R, Benayed R, Syed A . Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015; 17(3):251-64. PMC: 5808190. DOI: 10.1016/j.jmoldx.2014.12.006. View

15.

Edwards A, Isserlin R, Bader G, Frye S, Willson T, Yu F . Too many roads not taken. Nature. 2011; 470(7333):163-5. DOI: 10.1038/470163a. View

16.

Kumar R, Chang L, Ellis M, Bose R . Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One. 2013; 8(6):e67980. PMC: 3694871. DOI: 10.1371/journal.pone.0067980. View

17.

Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S . BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009; 10(11):R130. PMC: 3091323. DOI: 10.1186/gb-2009-10-11-r130. View

18.

Finan C, Gaulton A, Kruger F, Lumbers R, Shah T, Engmann J . The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017; 9(383). PMC: 6321762. DOI: 10.1126/scitranslmed.aag1166. View

19.

Thurnherr T, Singer F, Stekhoven D, Beerenwinkel N . Genomic variant annotation workflow for clinical applications. F1000Res. 2016; 5:1963. PMC: 5130070. DOI: 10.12688/f1000research.9357.2. View

20.

Russ A, Lampel S . The druggable genome: an update. Drug Discov Today. 2005; 10(23-24):1607-10. DOI: 10.1016/S1359-6446(05)03666-4. View